Market Cap : 5.64 B | Enterprise Value : 9.24 B | PE Ratio : At Loss | PB Ratio : 1.10 |
---|
NYSE:PRGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:PRGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2022-08-13), Perrigo Co's Intrinsic Value: Projected FCF is $58.08. The stock price of Perrigo Co is $41.87. Therefore, Perrigo Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.7.
The historical rank and industry rank for Perrigo Co's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Perrigo Co was 3.49. The lowest was 0.54. And the median was 1.55.
The historical data trend for Perrigo Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Intrinsic Value: Projected FCF distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Perrigo Co's Free Cash Flow(6 year avg) = $359.58.
Perrigo Co's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Jun22) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | 359.584 | + | 4849.8 | * | 0.8) | / | 134.600 | |
= | 54.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Perrigo Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 41.87 | / | 54.258589214587 | |
= | 0.77 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Perrigo Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ives Alison | officer: EVP & Chief Scientific Officer | C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010 |
Hanson Kyle | officer: EVP & General Counsel | |
Bezerra Eduardo Guarita | officer: EVP & Chief Financial Officer | C/O FRESH DEL MONTE PRODUCE INC. PO BOX 149222 CORAL GABLES FL 33134 |
Ashford Orlando D | director | C/O AMERANT BANK 220 ALHAMBRA CR. CORAL GABLES FL 33134 |
Doyle Katherine C. | director | 100 ABBOTT PARK ROAD, AP6C-1N D032L ABBOTT PARK IL 60064 |
Sorota Richard S | officer: EVP & President CSCA | HARMAN INTERNATIONAL INDUSTRIES, INC. 1101 PENNSYLVANIA AVE, NW, #1010 WASHINGTON DC 20004 |
Mann Erica L | director | ONE KELLOGG SQUARE P.O. BOX 3599 BATTLE CREEK MI 49016-3599 |
Silcock Raymond | officer: EVP, Chief Financial Officer | 399 JEFFERSON ROAD PARSIPPANY NJ 07054 |
Willis Robert | officer: Acting CHRO | C/O PERRIGO COMPANY PLC 515 EASTERN AVENUE ALLEGAN MI 49010 |
Dillard James E Iii | officer: EVP, Chief Scientific Officer | 6601 WEST BROAD STREET RICHMOND VA 23230 |
Kessler Murray S | director, officer: CEO | 714 GREEN VALLEY ROAD GREENSBORO NC 27408 |
Smith Jeffrey C | director | 777 THIRD AVENUE, 18TH FLOOR NEW YORK NY 10017 |
Roehrhoff Uwe | director, officer: CEO | C/O PERRIGO COMPANY PLC TREASURY BUILDING, LOWER GRAND CANAL ST DUBLIN L2 D2 |
Classon Rolf A | director | C/O CATALENT, INC. 14 SCHOOLHOUSE ROAD SOMERSET NJ 08873 |
Karaboutis Adriana | director | C/O BIOGEN IDEC INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire 11-02-2021
By PRNewswire 04-04-2022
Other Sources
By Zacks 2022-02-21
By Zacks 2021-12-07
By Zacks 2022-02-15
By Zacks 2022-03-01
By Zacks 2022-03-31
By Zacks 2022-02-15
By Zacks 2022-02-28
By Zacks 2021-11-10
By Fool 2021-11-10
By Zacks 2022-02-15
By Zacks 2022-02-10
By Fool 2022-03-01
By Zacks 2022-02-08
By Seekingalpha 2022-01-09